D-1436-2014 Class III Terminated
FDA drug recall D-1436-2014 was initiated by Teva Pharmaceuticals USA on Jun 17, 2014 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification impurity test results. The recall status is terminated (terminated Mar 9, 2015). Affected quantity: 1104 blister packs.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 23, 2014
- Initiation Date
- Jun 17, 2014
- Termination Date
- Mar 9, 2015
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1104 blister packs
Product description
Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sellersville, PA. NDC 0555-9043-58
Reason for recall
Failed Impurities/Degradation Specifications: out of specification impurity test results.
Distribution pattern
Nationwide
Code information
Lot 3805324A Exp. 11/14
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1436-2014
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026